Anzeige
Mehr »
Montag, 25.08.2025 - Börsentäglich über 12.000 News
Mega-Deal in Kanada: Katapultiert sich diese Aktie jetzt in die Top-Liga der Explorer?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
231 Leser
Artikel bewerten:
(1)

UK Health Tech Company Zedsen Closes $12M Series B, and Expands Executive Team with New Appointment of Dr. Caroline Hargrove as CTO

Evolving from a laboratory breakthrough in sensing technology and supported by 46 patents, Zedsen is one of the UKs fastest-growing health tech companies

LONDON, April 6, 2021 /PRNewswire/ -- Zedsen, a UK health tech company with a revolutionary non-invasive technology that helps consumers understand their health based on data coming from their bloodstream, today announced a $12 million Series B investment at a $110 million valuation, while also appointing Dr. Caroline Hargrove, former CTO of Babylon Health, as Chief Technology Officer.

The investors include: Joseph R. Grano, former Chairman and CEO of UBS Financial Services Inc; Nasser Kazeminy, Investor, Founder of NJK Holding and Chairman of the Ellis Island Honor Society (EIHS); Tony Rice, Former CEO of Cable and Wireless; Bonnie Mcalveen Hunter, Chairperson of the Red Cross; and Jim Harpel, Investor at Palm Beach Capital.

The addition of Dr. Hargrove and the new investors bring Zedsen closer to its mission to bring true, continuous, proactive health to everyone. Every health app created so far relies on data gleaned from outside the body, such as heart rate, temperature and movement. Some, such as apps for monitoring diabetes, get data from the blood, but only invasively, requiring needles or patches that puncture the skin.

What's been missing is a way to add important biophysical data from the bloodstream - continuously, comfortably, and without requiring needles or any action from the user. Zedsen's world-first technology provides that crucial window into the body through a sensor that sits on the skin's surface. By analyzing the combination of internal and external data, Zedsen can more precisely and richly give users an understanding of their health so they can make small lifestyle changes that have significant long term benefits.

The potential use cases are wide-ranging. Trends towards prediabetes can be spotted and reversed; fertility can be tracked; diets can be understood and tailored to each unique biological response.

"Low-cost, non-invasive technology for monitoring blood to a high standard is the holy grail that has profound, life-enhancing impact - whether you are monitoring metabolic health to improve athletic performance, or working to reverse the trend towards diabetes. I'm delighted to be working on developing such transformative products based on Zedsen's novel non-invasive technology and being part of Zedsen's amazing team," said Dr. Hargrove.

Renowned for her visionary leadership and ambition for future healthcare, Dr. Hargrove brings an impressive portfolio of experience to the team. Dr. Hargrove received a Commander of the Order of the British Empire (CBE) medal from The Queen for services to Engineering; won CBI's First Women of Engineering and Manufacturing award; was named one of the 50 most influential Women Engineers in the UK by The Telegraph; was a Founder and CTO of McLaren Applied Technologies; and since 2018 was CTO of $2 billion telehealth pioneer Babylon Health.

"Caroline's technical expertise will be intrinsic to the next stage of our journey, but most importantly, we are inspired and excited by her vision for hyper-personalised healthcare," said Zedsen CEO Daniel Honeywell. "Neither of us can accept the status quo. Chronic disease accounts for 41 million avoidable deaths each year. Knowing this can be prevented through meaningful biological insights and manageable lifestyle changes will allow us to actually deliver on the promise of proactive, personalized and preventative care."

About Zedsen

Zedsen is on a mission to make true, continuous proactive health a reality for everyone by helping people understand the inner workings of their bodies so they can stay their healthiest longer.The company's world-first technology unobtrusively gathers key biological signals from the bloodstream using non-invasive sensors. Data gathered leads to hyper-personalised insights about health, fitness and diet, with support and suggestions as unique as each individual user. Small lifestyle changes have significant impact by helping to prevent and reverse trends towards harmful conditions, and keep us healthier for longer.

Just as personalized data has the power to change the individual, collective data changes the world. Anonymised population data to allow for macro level research and changes in global healthcare. www.zedsen.com

© 2021 PR Newswire
Zeitenwende! 3 Uranaktien vor der Neubewertung
Ende Mai leitete US-Präsident Donald Trump mit der Unterzeichnung mehrerer Dekrete eine weitreichende Wende in der amerikanischen Energiepolitik ein. Im Fokus: der beschleunigte Ausbau der Kernenergie.

Mit einem umfassenden Maßnahmenpaket sollen Genehmigungsprozesse reformiert, kleinere Reaktoren gefördert und der Anteil von Atomstrom in den USA massiv gesteigert werden. Auslöser ist der explodierende Energiebedarf durch KI-Rechenzentren, der eine stabile, CO₂-arme Grundlastversorgung zwingend notwendig macht.

In unserem kostenlosen Spezialreport erfahren Sie, welche 3 Unternehmen jetzt im Zentrum dieser energiepolitischen Neuausrichtung stehen, und wer vom kommenden Boom der Nuklearindustrie besonders profitieren könnte.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche Aktien besonders von der Energiewende in den USA profitieren dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.